New York State Common Retirement Fund Buys 22,257 Shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC)

Key Points

• The New York State Common Retirement Fund increased its holdings in Oric Pharmaceuticals by 137.1% in Q1, now owning shares valued at $215,000.
• Insider trading activities included Director Angie You purchasing 26,597 shares at $9.39, while CFO Dominic Piscitelli sold 32,466 shares at an average price of $10.50.
• Wall Street analysts have a consensus buy rating for Oric Pharmaceuticals, with a target price average of $18.57, despite recent fluctuations with shares opening at $11.44.

New York State Common Retirement Fund boosted its holdings in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 137.1% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 38,486 shares of the company's stock after acquiring an additional 22,257 shares during the quarter. New York State Common Retirement Fund owned 0.05% of Oric Pharmaceuticals worth $215,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of ORIC. Arizona State Retirement System purchased a new position in shares of Oric Pharmaceuticals during the first quarter worth about $56,000. Wellington Management Group LLP lifted its position in Oric Pharmaceuticals by 6.9% during the fourth quarter. Wellington Management Group LLP now owns 186,430 shares of the company's stock valued at $1,504,000 after purchasing an additional 12,042 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Oric Pharmaceuticals by 54.5% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 35,579 shares of the company's stock worth $287,000 after buying an additional 12,545 shares in the last quarter. Two Sigma Advisers LP increased its holdings in shares of Oric Pharmaceuticals by 14.3% in the 4th quarter. Two Sigma Advisers LP now owns 66,500 shares of the company's stock worth $537,000 after buying an additional 8,300 shares during the last quarter. Finally, Tema Etfs LLC bought a new position in shares of Oric Pharmaceuticals in the 4th quarter worth $367,000. Hedge funds and other institutional investors own 95.05% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Oppenheimer dropped their price objective on shares of Oric Pharmaceuticals from $15.00 to $12.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. Wedbush reaffirmed an "outperform" rating and set a $20.00 price target on shares of Oric Pharmaceuticals in a research note on Monday, June 23rd. HC Wainwright reiterated a "buy" rating and set a $21.00 price objective on shares of Oric Pharmaceuticals in a research report on Monday, May 5th. LADENBURG THALM/SH SH started coverage on Oric Pharmaceuticals in a report on Tuesday, July 8th. They set a "buy" rating and a $15.00 price objective on the stock. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Oric Pharmaceuticals in a research note on Tuesday, May 6th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $18.57.

Insider Buying and Selling at Oric Pharmaceuticals

In other news, CFO Dominic Piscitelli sold 32,466 shares of the company's stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $10.50, for a total transaction of $340,893.00. Following the completion of the transaction, the chief financial officer directly owned 68,317 shares of the company's stock, valued at approximately $717,328.50. This represents a 32.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Angie You bought 26,597 shares of the company's stock in a transaction dated Friday, June 20th. The shares were purchased at an average price of $9.39 per share, with a total value of $249,745.83. Following the completion of the acquisition, the director owned 26,597 shares of the company's stock, valued at $249,745.83. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 40,000 shares of company stock worth $416,289. 6.82% of the stock is owned by insiders.

Oric Pharmaceuticals Stock Down 3.0%

Shares of NASDAQ ORIC traded down $0.33 during midday trading on Wednesday, reaching $10.71. The company had a trading volume of 882,486 shares, compared to its average volume of 1,131,564. The stock has a market cap of $912.71 million, a PE ratio of -5.73 and a beta of 1.54. Oric Pharmaceuticals, Inc. has a one year low of $3.90 and a one year high of $14.67. The firm's fifty day moving average price is $9.69 and its 200-day moving average price is $8.12.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported ($0.42) EPS for the quarter, topping analysts' consensus estimates of ($0.51) by $0.09. As a group, equities research analysts expect that Oric Pharmaceuticals, Inc. will post -2.17 EPS for the current year.

Oric Pharmaceuticals Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.